Current Trends in Mouse Models of Glioblastoma

Overview

Journal J Neurooncol

Publisher Springer

Date 2017 Oct 21

PMID 29052807

Citations 54

Authors

Masafumi Miyai

Hiroyuki Tomita

Akio Soeda

Hirohito Yano

Toru Iwama

Akira Hara

Affiliations

Soon will be listed here.

Abstract

Glioblastoma is the most deadly brain tumor type and is characterized by a severe and high rate of angiogenesis, remaining an incurable disease in the majority of cases. Mechanistic understanding of glioblastoma initiation and progression is complicated by the complexity of genetic and/or environmental initiating events and lack of clarity regarding the cell or tissue of origin. To determine these mechanisms, mouse models that recapitulate the molecular and histological characteristics of glioblastoma are required. Unlike in other malignancies, viral-mediated mouse models of glioblastoma rather than chemically induced mouse models have been developed because of its sensitivity to viruses. Based on recent molecular analyses reported for human glioblastoma, this review critically evaluates genetically engineered, xenograft, allograft, viral-mediated, and chemically induced mouse models of glioblastoma. Further, we focus on the clinical value of these models by examining their contributions to studies of glioblastoma prevention, tumorigenesis, and chemoresistance.

Citing Articles

Microtubule actin crosslinking factor 1, a brain tumor oncoprotein (Review).

Bonner K, Quick Q Mol Clin Oncol. 2024; 22(2):15.

PMID: 39720461 PMC: 11667447. DOI: 10.3892/mco.2024.2810.

Pediatric Hemispheric High-Grade Gliomas and H3.3-G34 Mutation: A Review of the Literature on Biological Features and New Therapeutic Strategies.

Bonada M, Pittarello M, De Fazio E, Gans A, Alimonti P, Slika H Genes (Basel). 2024; 15(8).

PMID: 39202398 PMC: 11353413. DOI: 10.3390/genes15081038.

Intratumoral Cell Heterogeneity in Patient-Derived Glioblastoma Cell Lines Revealed by Single-Cell RNA-Sequencing.

Arbatskiy M, Balandin D, Churov A, Varachev V, Nikolaeva E, Mitrofanov A Int J Mol Sci. 2024; 25(15).

PMID: 39126040 PMC: 11313325. DOI: 10.3390/ijms25158472.

Chlorpromazine overcomes temozolomide resistance in glioblastoma by inhibiting Cx43 and essential DNA repair pathways.

Matarrese P, Signore M, Ascione B, Fanelli G, Paggi M, Abbruzzese C J Transl Med. 2024; 22(1):667.

PMID: 39026284 PMC: 11256652. DOI: 10.1186/s12967-024-05501-3.

Integrating Ataxia Evaluation into Tumor-Induced Hearing Loss Model to Comprehensively Study NF2-Related Schwannomatosis.

Lu S, Yin Z, Chen J, Wu L, Sun Y, Gao X Cancers (Basel). 2024; 16(11).

PMID: 38893082 PMC: 11171041. DOI: 10.3390/cancers16111961.

References

Pandita A, Aldape K, Zadeh G, Guha A, James C . Contrasting in vivo and in vitro fates of glioblastoma cell subpopulations with amplified EGFR. Genes Chromosomes Cancer. 2003; 39(1):29-36. DOI: 10.1002/gcc.10300. View

von Jonquieres G, Mersmann N, Klugmann C, Harasta A, Lutz B, Teahan O . Glial promoter selectivity following AAV-delivery to the immature brain. PLoS One. 2013; 8(6):e65646. PMC: 3683058. DOI: 10.1371/journal.pone.0065646. View

Johanns T, Ward J, Miller C, Wilson C, Kobayashi D, Bender D . Endogenous Neoantigen-Specific CD8 T Cells Identified in Two Glioblastoma Models Using a Cancer Immunogenomics Approach. Cancer Immunol Res. 2016; 4(12):1007-1015. PMC: 5215735. DOI: 10.1158/2326-6066.CIR-16-0156. View

Taillandier L, Antunes L, Angioi-Duprez K . Models for neuro-oncological preclinical studies: solid orthotopic and heterotopic grafts of human gliomas into nude mice. J Neurosci Methods. 2003; 125(1-2):147-57. DOI: 10.1016/s0165-0270(03)00043-8. View

Louis D, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee W . The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016; 131(6):803-20. DOI: 10.1007/s00401-016-1545-1. View

Hambardzumyan D, Amankulor N, Helmy K, Becher O, Holland E . Modeling Adult Gliomas Using RCAS/t-va Technology. Transl Oncol. 2009; 2(2):89-95. PMC: 2670576. DOI: 10.1593/tlo.09100. View

Gousias K, Markou M, Arzoglou V, Voulgaris S, Vartholomatos G, Kostoula A . Frequent abnormalities of the immune system in gliomas and correlation with the WHO grading system of malignancy. J Neuroimmunol. 2010; 226(1-2):136-42. DOI: 10.1016/j.jneuroim.2010.05.027. View

Zhu Y, Guignard F, Zhao D, Liu L, Burns D, Mason R . Early inactivation of p53 tumor suppressor gene cooperating with NF1 loss induces malignant astrocytoma. Cancer Cell. 2005; 8(2):119-30. PMC: 3024718. DOI: 10.1016/j.ccr.2005.07.004. View

Cho J, Pastorino S, Zeng Q, Xu X, Johnson W, Vandenberg S . Glioblastoma-derived epidermal growth factor receptor carboxyl-terminal deletion mutants are transforming and are sensitive to EGFR-directed therapies. Cancer Res. 2011; 71(24):7587-96. PMC: 3242822. DOI: 10.1158/0008-5472.CAN-11-0821. View

10.

Uhrbom L, Dai C, Celestino J, Rosenblum M, Fuller G, Holland E . Ink4a-Arf loss cooperates with KRas activation in astrocytes and neural progenitors to generate glioblastomas of various morphologies depending on activated Akt. Cancer Res. 2002; 62(19):5551-8. View

11.

Kessler J, Kahle K, Sun T, Meerbrey K, Schlabach M, Schmitt E . A SUMOylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesis. Science. 2011; 335(6066):348-53. PMC: 4059214. DOI: 10.1126/science.1212728. View

12.

Mathieu V, De Neve N, Mercier M, Dewelle J, Gaussin J, Dehoux M . Combining bevacizumab with temozolomide increases the antitumor efficacy of temozolomide in a human glioblastoma orthotopic xenograft model. Neoplasia. 2008; 10(12):1383-92. PMC: 2586689. DOI: 10.1593/neo.08928. View

13.

Giannini C, Sarkaria J, Saito A, Uhm J, Galanis E, Carlson B . Patient tumor EGFR and PDGFRA gene amplifications retained in an invasive intracranial xenograft model of glioblastoma multiforme. Neuro Oncol. 2005; 7(2):164-76. PMC: 1871885. DOI: 10.1215/S1152851704000821. View

14.

Fraser H . Astrocytomas in an inbred mouse strain. J Pathol. 1971; 103(4):266-70. DOI: 10.1002/path.1711030410. View

15.

Furnari F, Fenton T, Bachoo R, Mukasa A, Stommel J, Stegh A . Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev. 2007; 21(21):2683-710. DOI: 10.1101/gad.1596707. View

16.

Suggitt M, Bibby M . 50 years of preclinical anticancer drug screening: empirical to target-driven approaches. Clin Cancer Res. 2005; 11(3):971-81. View

17.

Mahesparan R, Read T, Lund-Johansen M, Skaftnesmo K, Bjerkvig R, Engebraaten O . Expression of extracellular matrix components in a highly infiltrative in vivo glioma model. Acta Neuropathol. 2002; 105(1):49-57. DOI: 10.1007/s00401-002-0610-0. View

18.

Parsons D, Jones S, Zhang X, Cheng-Ho Lin J, Leary R, Angenendt P . An integrated genomic analysis of human glioblastoma multiforme. Science. 2008; 321(5897):1807-12. PMC: 2820389. DOI: 10.1126/science.1164382. View

19.

Ding H, Shannon P, Lau N, Wu X, Roncari L, Baldwin R . Oligodendrogliomas result from the expression of an activated mutant epidermal growth factor receptor in a RAS transgenic mouse astrocytoma model. Cancer Res. 2003; 63(5):1106-13. View

20.

Wykosky J, Hu J, Gomez G, Taylor T, Villa G, Pizzo D . A urokinase receptor-Bim signaling axis emerges during EGFR inhibitor resistance in mutant EGFR glioblastoma. Cancer Res. 2014; 75(2):394-404. PMC: 4297573. DOI: 10.1158/0008-5472.CAN-14-2004. View